We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NK cells

News List

Celularity Doses First Patient in Trial Evaluating CYNK-001 in COVID-19 Patients americanpharmaceuticalreview
September 24, 2020
Celularity announced the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial.
Kiadis to collaborate with Abigail Wexner Research Institute for clinical trials of COVID-19 therapy expresspharma
September 15, 2020
The US FDA approved AWRI’s investigational new drug application (IND) for a study in an adult population with off-the-shelf natural killer (NK) cells.
Therapeutic Solutions to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19 americanpharmaceuticalreview
July 02, 2020
Therapeutics Solutions has announced plans to utilize its clinical-stage cancer immunotherapy StemVacs™ for treatment of COVID-19 patients.
Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies pharmaceutical-business-review
April 26, 2020
Gilead Sciences and its subsidiary Kite have joined forces with oNKo-innate to discover and develop cancer immunotherapies focused on natural killer (NK) cells.